ImmuPharma (LON:IMM) Stock Price Up 8.6% – Should You Buy?

Shares of ImmuPharma plc (LON:IMM) traded up 8.6% during mid-day trading on Friday. The company traded as high as GBX 3.61 and last traded at GBX 3.26. Approximately 8,074,562 shares traded hands during mid-day trading, an increase of 224% from the average session volume of 2,488,500 shares. The stock had previously closed at GBX 3.

ImmuPharma Price Performance

The firm’s fifty day moving average price is GBX 3.61 and its 200-day moving average price is GBX 4.67. The company has a market cap of £20.63 million, a price-to-earnings ratio of -3.98 and a beta of 3.02.

ImmuPharma (LON:IMM) last released its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. As a group, equities analysts forecast that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.